ECP effective in the long-term

Article

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Dr Lima and colleagues conducted a long-term retrospective study of ECP in refractory glaucomas that included 539 eyes of 485 patients. Each subject underwent one ECP and were followed-up for a minimum five-year period, and retrospectively reviewed. Limbal or pars plana ECP was performed for 210 degrees with scleral depression of the ciliary body.Preoperative IOP was 37.9±6.4 mmHg, diminishing to 15.7±8.5 mmHg. The average number of surgeries preoperatively was 2.2 and the mean number of preoperative medications was 3.9±0.6, reducing postoperatively to 1.5±1.1. Success at one and five years postoperatively (defined as IOP between 5 and 22 mmHg) was 92.6% and 78.8%, respectively. Complications included fibrin exudates (21.5%), failed corneal graft (19.7%), hyphaema (10.7%), immediate postoperative IOP spike (9.8%), choroidal detachment (5.8%), phthisis (2.4%), retinal detachment (1.5%) and hypotony (1.3%).

The authors of this study believe that the results demonstrate the effectiveness of ECP as a long-term management approach for refractory glaucoma and recommend that it be considered as a first-line treatment.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.